Compare VST & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VST | REGN |
|---|---|---|
| Founded | 1882 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0B | 73.9B |
| IPO Year | N/A | 1991 |
| Metric | VST | REGN |
|---|---|---|
| Price | $168.50 | $755.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 23 |
| Target Price | $234.09 | ★ $795.74 |
| AVG Volume (30 Days) | ★ 4.1M | 1.1M |
| Earning Date | 11-06-2025 | 02-03-2026 |
| Dividend Yield | ★ 0.53% | 0.47% |
| EPS Growth | N/A | ★ 2.88 |
| EPS | 2.77 | ★ 41.59 |
| Revenue | ★ $17,191,000,000.00 | $14,247,800,000.00 |
| Revenue This Year | $15.69 | $1.95 |
| Revenue Next Year | $13.95 | $5.47 |
| P/E Ratio | $61.31 | ★ $17.82 |
| Revenue Growth | ★ 5.69 | 2.89 |
| 52 Week Low | $90.51 | $476.49 |
| 52 Week High | $219.82 | $790.98 |
| Indicator | VST | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.54 | 61.81 |
| Support Level | $158.65 | $689.88 |
| Resistance Level | $180.00 | $753.61 |
| Average True Range (ATR) | 6.86 | 20.54 |
| MACD | 0.56 | -4.09 |
| Stochastic Oscillator | 45.23 | 65.15 |
Vistra Corp. is one of the largest power producers and retail energy providers in the US. Following the 2024 Energy Harbor acquisition, Vistra owns 41 gigawatts of nuclear, coal, natural gas, solar, and energy storage assets. The Lotus Partners asset purchase would add 2.6 GW of natural gas generation. Its retail electricity business serves 5 million customers in 20 states, including almost a third of all Texas electricity consumers. Vistra emerged from the Energy Future Holdings bankruptcy as a stand-alone entity in 2016. It acquired Dynegy in 2018.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).